Rifalazil

Rifalazil is an antibiotic that belongs to the rifamycin group. It is primarily used in the treatment of tuberculosis and other bacterial infections.

History[edit | edit source]

Rifalazil was first synthesized in the 1980s by the pharmaceutical company Hoffmann-La Roche. It was developed as a part of the company's efforts to create new antibiotics that could combat drug-resistant strains of bacteria.

Mechanism of Action[edit | edit source]

Rifalazil works by inhibiting the RNA polymerase enzyme in bacteria, which is essential for the synthesis of RNA and protein. By blocking this enzyme, the antibiotic prevents the bacteria from growing and reproducing.

Clinical Use[edit | edit source]

Rifalazil is used in the treatment of various bacterial infections, including tuberculosis, leprosy, and Legionnaires' disease. It is also used in the treatment of Chlamydia pneumoniae, a common cause of pneumonia.

Side Effects[edit | edit source]

Like all antibiotics, Rifalazil can cause side effects. The most common side effects include nausea, vomiting, and diarrhea. In rare cases, it can cause more serious side effects such as liver damage or allergic reactions.

Resistance[edit | edit source]

Bacterial resistance to Rifalazil is a growing concern. Resistance occurs when bacteria evolve mechanisms to survive exposure to the antibiotic. This can occur through the mutation of the RNA polymerase enzyme, rendering Rifalazil ineffective.

See Also[edit | edit source]

Need help finding a doctor or specialist anywhere in the world? WikiMD's DocFinder can help with millions of doctors!

This article is a stub. Help WikiMD grow by registering to expand it. Editing is available only to registered and verified users. About WikiMD: A comprehensive, free health & wellness encyclopedia.